Studies within the Adult Respiratory Research Group
Updated August 2015
Non-interventional Studies
| Title |
Principle Investigator | Funding |
|---|---|---|
| Biomarkers to target antibiotic and systemic corticosteroid therapy in COPD Exacerbations | Christopher Brightling | Research Council |
| An open study to measure imaging biomarkers and inflammatory cells, mediators and biomarkers from blood, urine and airway samples from healthy volunteers, asthma patients and COPD patients in stable disease and during acute exacerbation. | Christopher Brightling | Other non-commercial |
| Emphysema Versus Airways | Christopher Brightling | European commission |
| Longitudinal Quantitative Analysis of Airway Remodelling and Airflow Dynamics in Airway Diseases | Christopher Brightling | Industry Collaborative |
| Gene expression profiling in mild and severe asthma, eosinophilic bronchitis and normal controls | Peter Bradding | Industry Collaborative |
| Molecular and Functional Mechanisms of Human Lung Disease | Andrew Wardlaw | Other non-commercial |
| Characterisation of the clinical and immunopathological features of eosinophilic bronchitis | Christopher Brightling | Research Charity |
| Studies on Aspergillus Lung Disease | Andrew Wardlaw | Research Council |
| Prospective study Of Fibrosis In the Lung Endpoints | Sanjay Agrawal | Research Council |
| Studies of leucocyte activation and migration | Andrew Wardlaw | Research Council |
| Proteomics in induced sputum in patients with lung cancer | Peter Bradding | Other non- commercial |
| The Pathophysiology of Interstitial Lung Disease | Peter Bradding | Other non- commercial |
| Measuring Lung development using Helium-3 magnetic resonance | Erol Gaillard | Other non- commercial |
| Molecular genetics of adverse drug reactions | Nasreen Khan | Research Council |
| Leicester Asthma Tissue Bank | Peter Bradding | Other non- commercial |
| The value of measuring airway inflammation in the management of asthma - follow up study | Christopher Brightling | Other non- commercial |
| Genetic causes of chronic cough and neuropathy | Martin Tobin | Research Council |
| Airway colonisation and sensitisation with Aspergillus fumigatus and other fungi in children with asthma (FAST) | Erol Gaillard | Research Charity |
| Deep phenotyping of the quadriceps muscle in patients with Chronic Obstructive Pulmonary Disease (COPD) | Mick Steiner | Research Council |
| An observational study examining airway remodelling and repair in patients with severe persistant asthma treated with bronchial thermoplasty: an imaging and immunopathological study | Christopher Brightling | non interventional |
| Extended Cohort for e- health, environment and DNA (EXCEED) study | Martin Tobin | Research Council |
| Physical activity and respiratory Health (phARaoh) study | Michael Morgan | Research Council |
| Alpha-1-antitrypsin Deficiency Assessment and programme for Treatment (ADAPT) | Michael Steiner | DH/NIHR |
| Respiratory Research Database | Rob Free | BRU |
| Establishing what relationship exists between fungal colonisation and allergy and the clinical, radiological and pathological characteristics of lung disease | Andrew Wardlaw | Other non commercial |
|
AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS) Multinational, multicentre, non-pharmacological intervention, cross-sectional and longitudinal study. |
Salman Siddiqui | Industry contract |
Interventional Studies
| Title | Principle Investigator | Funding |
|---|---|---|
| Prognostic value of Interferon Gamma Release Assays in predicting active tuberculosis among individuals with, or at risk of, latent tuberculosis infection - The UK PREDICT Study | Pranab Haldar | Research Council |
| A comprehensive comparison of the sensitivity of common exercise outcome measures for Chronic Obstructive Pulmonary Disease (COPD) | Sally Singh | Industry collaborative |
| A multi-centre, open-label, long term safety study of mepolizumab in asthmatic subjects who participated in the MEA112997 trial. | Christopher Brightling | Industry contract |
| The clinical and cost effectiveness of temporarily quaprupling the dose of inhaled steroid to prevent asthma exacerbations; a pragmatic, randomised, normal care controlled, clinical trial | Christopher Brightling (change of PI) | Research Council |
| WB28182 The effect of Lebrikizumab in patients with severe asthma | Peter Bradding | Industry contract |
| Study of Eosinophilic Granulomatosis with polyangiitis and Mepolizumab | Andrew Wardlaw | Industry contract |
| GS-6624 in subjects with Idiopathic Pulmonary Fibrosis (RAINIER) | Sanjay Agrawal | Industry contract |
| Post authorisation safety study of Esbriet (PASSPORT) | Sanjay Agrawal | Industry contract |
| A Phase II, randomised, observer-blind, placebocontrolled, multi-centre study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ investigational vaccine GSK2838504A, when administered intramuscularly according to a 0, 2 month schedule to COPD patients aged 40 to 80 years | Christopher Brightling | Industry contract |
| An exploratory, 12 week, randomised, partially double-blinded, placebo-controlled, parallel group trial to explore the effects of once daily treatments of orally inhaled tiotropium + olodaterol fixed dose combination or tiotropium (both delivered by the Respimat® inhaler), supervised exercise training and behaviour modification on exercise capacity and physical activity in patients with Chronic Obstructive Pulmonary Disease (COPD) | Rachel Evans | Industry contract |
| A multi-centre randomised, double blind, placebo-controlled, parallel group trial of the effectiveness of the nocturnal use of a Temperature Controlled Laminar Airflow (TLA) Device (Airsonett®) in adults with poorly-controlled, severe allergic asthma | Peter Bradding | Research Council |
| A Multi-Centre, Open-Label, Study of Mepolizumab in a Subset of Subjects with a History of Life Threatening/Seriously Debilitating Asthma Who Participated in the MEA115661 Trial | Christopher Brightling | Industry contract |
| A Randomised, Double-blind, Chronic Dosing (56 week) Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of 2 Doses of Benralizumab (MEDI-563) in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (GALATHEA) | Christopher Brightling | Industry Contract |
| Phenotyping bronchiectasis based on aetiology, exacerbation characteristics and response to erythromycin | Andrew Wardlaw | BRU |
| A 52 week multi centre randomised double blind parallel group placebo controlled phase III study to evaulate the efficacy and safety of Tralokinumab in adults and adolescents with asthma inadequately controlled on inhaled corticosteriods plus long acting beta 2 agonist (D2210C00008). | Christopher Brightling | Industry contract |
| A study to evaluate the efficacy of a SIMPLE intervention to support medicine adherence for people with difficult-to-control asthma | Anna Murphy | Industry contract |
| Treatment of Chronic Idiopathic Cough (CIC0 and Chronic Cough in patients with idiopathic pulmonary fibrosis with PA101 | Sanjay Agrawal | Industry contract |
